AustralianSuper’s Neurocrine Biosciences NBIX Stock Holding History

AustralianSuper’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$58.8M	Buy	+348,993	New	+$51.8M	0.25%	90
2023 Q2	–	Sell	-62,467	Closed	-$6.32M	–	293
2023 Q1	$6.32M	Buy	+62,467	New	+$6.5M	0.04%	150
2022 Q1	–	Sell	-73,792	Closed	-$6.4M	–	198
2021 Q4	$6.4M	Sell	73,792 -62,037	-46%	-$5.71M	0.03%	176
2021 Q3	$13M	Sell	135,829 -71,451	-34%	-$6.75M	0.08%	140
2021 Q2	$20.2M	Buy	207,280 +33,076	+19%	+$3.17M	0.14%	98
2021 Q1	$16.9M	Buy	174,204 +139,732	+405%	+$14.7M	0.13%	97
2020 Q4	$3.3M	Buy	+34,472	New	+$3.33M	0.02%	124

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

AustralianSuper's NBIX Position: Q2 2026 in Review

AustralianSuper opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 348,993 shares worth $58.8M. The stake represents 0.25% of the portfolio and ranks #90 among its holdings. This is a return to the name: AustralianSuper previously reported a position in NBIX as recently as Q1 2023.

AustralianSuper first reported a position in NBIX in Q4 2020 and has held it in 7 quarters since. 776 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

AustralianSuper held 348,993 shares of Neurocrine Biosciences worth $58.8M as of Q2 2026.
Neurocrine Biosciences was a new AustralianSuper position in Q2 2026.
Neurocrine Biosciences made up 0.25% of AustralianSuper's portfolio in Q2 2026, its #90 holding.
AustralianSuper first reported a position in Neurocrine Biosciences in Q4 2020 and has held it in 7 quarters since.
776 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on AustralianSuper's 13F filing for Q2 2026, filed 12 Aug 2026.